Cipla
BSE 500087
4 stories, newest first.
- USFDA inspection at InvaGen facility concludes with zero Form 483 observations
- Analyst discussion on freight cost pressure impacting revenue this quarter, and the Lanreotide impact on Cipla's US/North America business
- Cipla to release Q2FY27 unaudited results and host earnings conference call on 27 October 2026
- Board Meeting on 27 October 2026 for Q2 and Half-Year Results
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.